Partager
))
Hosted by former Marvel entertainment lawyer Paul Sarker and entertainment enthusiast Mesh Lakhani, Better Call Paul will delve into the business and legal issues at play behind the glitz and glam. This show takes you beyond the catchy headlines to find out what’s really at play behind the scenes and gives you an introduction to the business side of show business.
…
continue reading
Is the FDA Too Cautious?
Manage episode 371829515 series 2140049
Contenu fourni par Open to Debate. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Open to Debate ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
While the Food and Drug Administration (FDA) needs to approve safe and effective drugs as quickly as possible to patients who need them, it must also maintain the diligence and rigor necessary to prevent harm. Two health experts look at the pace of FDA approvals and argue about whether the agency is getting it right on keeping the public safe or stifling health innovations. Now we debate: Is the FDA Too Cautious?
Arguing Yes: Colin Hill, CEO & Co-Founder, Aitia
Arguing No: Peter Lurie, President and Executive Director of Center for Science in the Public Interest
Emmy award-winning journalist John Donvan moderates
Learn more about your ad choices. Visit podcastchoices.com/adchoices
344 episodes
